Clinical Study

Involvement of Differential Relationship between HCV Replication and Hepatic PRR Signaling Gene Expression in Responsiveness to IFN-Based Therapy

Nobukazu Yuki,¹ Shinji Matsumoto,² Michio Kato,³ and Toshikazu Yamaguchi²

¹ Department of Gastroenterology, Osaka National Hospital, Hoenzaka 2-1-14, Chuo-ku, Osaka 540-0006, Japan

² BML, Inc., Kawagoe 350-1101, Japan

³ Department of Gastroenterology, Minamiwakayama National Hospital, Tanabe 646-8558, Japan

Correspondence should be addressed to Nobukazu Yuki; yuki@onh.go.jp

Received 12 March 2013; Revised 14 November 2013; Accepted 2 December 2013

Academic Editor: Man-Fung Yuen

Copyright © 2013 Nobukazu Yuki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Aim. To gain an insight into the effect of HCV replication-associated interference with the IFN system on hepatic mRNA expression involved in IFN production. **Methods.** Relative mRNA expression of TLR3/RIG-I signaling genes involved in IFN- β production was correlated with positive- and negative-strand HCV RNAs in pretreatment liver tissues responsive and nonresponsive to peginterferon and ribavirin for chronic hepatitis C genotype 1. Treatment response was analyzed for per protocol population at weeks 12 ($n = 45$) and 24 ($n = 40$) and at 24 weeks after treatment ($n = 38$). **Results.** HCV replication had no relation to the expression of TLR3, RIG-I, TRIF, IPS-1, IRF3, and IFN- β mRNAs in responders. In striking contrast, positive- and/or negative-strand HCV showed positive correlations with TLR3, RIG-I, TRIF, IPS-1, and IRF3 mRNAs in week-12 nonresponders; with RIG-I, TRIF, IPS-1, and IRF3 mRNAs in week-24 nonresponders; and with TLR3, RIG-I, and IRF3 mRNAs in posttreatment nonresponders. Thus mRNA expression of TLR3/RIG-I signaling genes was increased in relation to viral replication in nonresponders. **Conclusions.** The findings in IFN nonresponders may imply a host feedback response to severe impairment of the IFN system associated with HCV replication.

1. Introduction

Upon recognition of hepatitis C virus (HCV) infection by Toll-like receptor 3 (TLR3) and retinoic-acid inducible gene I (RIG-I), the innate immune response is promptly activated in hepatocytes. The two pattern recognition receptors (PRRs) recruit their respective adaptors, Toll/interleukin-1 receptor-domain containing adaptor inducing interferon (IFN)- β (TRIF) and IFN- β promoter stimulator-1 (IPS-1), that relay the signal to downstream IFN regulatory factor-3 (IRF3), leading to the induction of IFN- β , known as the “front line” of host antiviral defenses in the liver [1, 2].

HCV has evolved highly successful multiple mechanisms for counteracting host antiviral responses. HCV NS3/4A serine protease in infected cells cleaves TRIF and IPS-1 and thereby disrupts the signal for IFN- β induction [3–5]. HCV interferes with various aspects of the downstream IFN action [6]. For example, HCV disrupts JAK-Stat signaling by NS5A

and inhibits protein kinase R by NS5A and E2 proteins. Recent studies demonstrated that interference of HCV proteins with IFN production and its action depends on the levels of HCV propagation [7, 8].

Under the circumstances, we hypothesized that HCV replication-associated interference with the host IFN system may cause changes in hepatic gene expression involved in IFN production at the mRNA levels and that, if so, this host feedback response may occur in different fashion according to responsiveness to IFN-based therapy as interference with the host IFN system is considered to be more severe in nonresponders. To gain an insight into this hypothesis, we measured hepatic mRNA expression involved in IFN- β production, and the results were correlated with copy numbers of liver positive- and negative-strand HCV RNAs using pretreatment liver tissues responsive to IFN-based treatment and liver tissues that were nonresponsive to the treatment.

TABLE 1: Patient characteristics regarding virologic response to PEG-IFN and ribavirin.

Characteristics	Response at week 12		Response at week 24		Posttreatment response	
	Yes	No	Yes	No	Yes	No
No.	14	31	26	14	22	16
Sex, M/F (% men)	10/4 (71)	19/12 (61)	17/9 (65)	9/5 (64)	16/6 (73)	9/7 (56)
Age	52 ± 11	59 ± 10	55 ± 11	59 ± 10	52 ± 10 ^a	61 ± 8
Previous IFN therapy, <i>n</i> (%)	3 (21)	15 (48)	7 (27)	7 (50)	5 (23) ^a	9 (56)
ALT (IU/L)	85 ± 63	77 ± 41	83 ± 55	68 ± 31	89 ± 57	60 ± 29
Serum HCV RNA (log IU/mL)	6.1 ± 0.6	6.2 ± 0.4	6.2 ± 0.5	6.2 ± 0.3	6.2 ± 0.5	6.2 ± 0.3
Liver inflammatory score	7.0 ± 2.1	7.0 ± 2.5	7.0 ± 2.1	6.7 ± 2.9	7.1 ± 2.3	6.6 ± 2.7
Liver fibrosis score	1.7 ± 1.2	2.2 ± 1.1	1.9 ± 1.2	2.2 ± 1.1	1.8 ± 1.2	2.4 ± 1.0

Variables are presented as mean ± SD.

^aStatistically significant difference $P < 0.05$ between responders and nonresponders.

2. Patients and Methods

2.1. Liver Tissues Responsive and Nonresponsive to IFN-Based Treatment. Liver tissues were obtained from 45 patients with chronic hepatitis C genotype 1 before 48-week treatment with weight-based doses of PEG-IFN- α 2b (PEG-Intron; MSD K.K., Tokyo, Japan) and ribavirin (Rebetol; MSD K.K.) [9]. A portion of the liver biopsy specimen was immediately frozen and stored at -80°C for real-time PCR. Slow virologic responders showing HCV RNA clearance after week 12 were assigned to 72-week extended treatment. Treatment response was analyzed for per protocol population at week 12 ($n = 45$), week 24 ($n = 40$), and 24 weeks aftertreatment ($n = 38$). Table 1 summarizes the study cohort regarding achievement of complete early virologic response (cEVR) (serum HCV RNA clearance at week 12), virologic response at week 24 (VR24) (HCV RNA clearance at week 24), and sustained virologic response (SVR) (HCV RNA clearance at 24 weeks aftertreatment). The SVR group was younger and tended to be more treatment-naïve than the non-SVR group. Otherwise, no difference was seen in gender, serum alanine aminotransferase (ALT), serum HCV RNA, and liver histology. The study was approved by the local research ethics committee in accordance with the 1975 Declaration of Helsinki, and all patients provided written informed consent.

2.2. Hepatic mRNA Quantitation. Relative mRNA expression of TLR3, RIG-I, TRIF, IPS-1, IRF3, and IFN- β was determined by real-time PCR [9]. Total hepatic RNA was extracted using the TRIzol Reagent (Invitrogen, Carlsbad, CA). One μg of RNA was denatured at 65°C for 5 min and reverse transcribed in a $20\mu\text{L}$ reaction mixture containing $4\mu\text{L}$ of $5\times$ reverse-transcription (RT) buffer (Invitrogen), $0.2\mu\text{mol}$ of DTT, 100 U of Superscript II (Invitrogen), 20 U of RNasin (Promega, Madison, WI), 10 nmol of each dNTP, and 100 pmol of random hexamers. The RT reaction was performed for 10 min at 25°C , 120 min at 42°C , and then 15 min at 70°C . Primers and probes for target and reference genes studied were purchased from Applied Biosystems (Foster City, CA) (TaqMan Gene Expression Assays Hs00152933.m1 [TLR3], Hs00184937.m1 [RIG-I], Hs00706140.s1 [TRIF], Hs00325038.m1 [IPS-1], Hs00155574.m1 [IRF3],

Hs0027188.s1 [IFN- β], and 4310884E [GAPDH]). The cDNA product was diluted 1:2.5, and $5\mu\text{L}$ was amplified in a $20\mu\text{L}$ reaction mixture containing $10\mu\text{L}$ of $2\times$ TaqMan Universal PCR Master Mix and $1\mu\text{L}$ of $20\times$ gene-specific primers and probe mixture (Applied Biosystems). PCR cycling was performed as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min, in an ABI PRISM 7900 Sequence Detection System (Applied Biosystems). Duplicate cycle threshold (Ct) values were analyzed by using the comparative Ct ($\Delta\Delta\text{Ct}$) method. The relative amount of target mRNA ($2^{-\Delta\Delta\text{Ct}}$) was obtained by normalization to an endogenous GAPDH reference and expressed relative to the amount from normal liver tissue derived from an HCV-uninfected individual who had received hepatectomy for a metastatic liver tumor.

2.3. Virologic and Histologic Evaluation. HCV replication was evaluated by serum HCV RNA levels (COBAS AMPLICOR HCV MONITOR Test v.2.0, Roche Diagnostics K.K., Tokyo, Japan) and copy numbers of liver positive- and negative-strand HCV RNAs as measured by strand-specific real-time PCR [10]. Liver histology was assessed using the Knodell score [11].

2.4. Statistical Analysis. Data on continuous variables were presented as mean ± SD. An arbitrary value of 0 was attributed to the liver tissues negative by PCR to detect host mRNAs and viral RNAs. The range of serum HCV RNA quantitation was from 3.7 to 6.7 log IU/mL. For statistics, an arbitrary value of 7 log IU/mL was attributed to HCV RNA levels of >6.7 log IU/mL. Group comparisons were performed by nonparametric tests (Wilcoxon and Mann-Whitney) for continuous variables and by Fisher's exact test for binary variables. Spearman rank order correlations were used to study the relationship between the variables. A value of $P < 0.05$ (two-tailed) was considered to indicate significance.

3. Results

The relationship of hepatic PRR signaling gene expression with hepatic and circulating HCV loads was analyzed regarding responsiveness to PEG-IFN and ribavirin. In liver tissues

TABLE 2: Correlations between HCV replication (liver positive- and negative-strand HCV RNAs and circulating HCV RNA) and hepatic PRR signaling gene expression regarding virologic response at week 24.

Hepatic gene expression		Responders at week 24 (<i>n</i> = 26)			Nonresponders at week 24 (<i>n</i> = 14)		
		Liver HCV RNA		Serum HCV RNA	Liver HCV RNA		Serum HCV RNA
		+Strand	–Strand		+Strand	–Strand	
TLR3 mRNA	<i>r</i>	0.149	0.173	0.100	0.407	0.442	0.066
	<i>P</i>	0.469	0.398	0.626	0.149	0.114	0.823
RIG-I mRNA	<i>r</i>	0.217	0.324	–0.070	0.797	0.744	0.513
	<i>P</i>	0.288	0.107	0.735	<0.001	0.002	0.060
TRIF mRNA	<i>r</i>	0.014	0.091	–0.254	0.659	0.620	0.280
	<i>P</i>	0.946	0.659	0.211	0.010	0.018	0.333
IPS-1 mRNA	<i>r</i>	0.012	0.100	–0.217	0.563	0.538	0.209
	<i>P</i>	0.952	0.627	0.288	0.036	0.047	0.473
IRF3 mRNA	<i>r</i>	0.023	–0.005	–0.312	0.647	0.521	0.189
	<i>P</i>	0.911	0.981	0.121	0.012	0.056	0.517
IFN- β mRNA	<i>r</i>	–0.154	–0.222	–0.174	0.433	0.411	–0.022
	<i>P</i>	0.453	0.275	0.394	0.122	0.144	0.940

showing cEVR, none of the mRNA expressions studied (TLR3, RIG-I, TRIF, IPS-1, IRF3, and IFN- β) showed a relationship with liver positive- and negative-strand HCV RNAs and circulating HCV RNA (see Supplementary Figure 1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2013/917261>). In contrast, mRNA expression of the PRR signaling genes involved in IFN- β production was uniformly increased in parallel with HCV loads in liver tissues nonresponsive at week 12. Liver positive- and/or negative-strand HCV RNA(s) showed positive correlations with the mRNA levels of TLR3 ($r = 0.396$, $P = 0.028$ and $r = 0.303$, $P = 0.097$), RIG-I ($r = 0.595$, $P < 0.001$ and $r = 0.682$, $P < 0.001$), TRIF ($r = 0.256$, $P = 0.165$ and $r = 0.414$, $P = 0.021$), IPS-1 ($r = 0.304$, $P = 0.096$ and $r = 0.358$, $P = 0.048$), and IRF3 ($r = 0.397$, $P = 0.027$ and $r = 0.384$, $P = 0.033$, resp.). However, the correlations of IFN- β mRNA with positive- and negative-strand HCV RNAs did not reach a significant level ($r = 0.309$, $P = 0.090$ and $r = 0.275$, $P = 0.134$, resp.). Unexpectedly, these figures in nonresponders were not seen when HCV propagation was assessed by circulating HCV loads. No relationship was found between serum HCV RNA levels and any mRNA expression in liver tissues (Figure 1). Supplementary Figure 2 represents the interrelationship of liver positive- and negative-strand HCV RNAs and serum HCV RNA in the study cohort. Liver positive- and negative-strand HCV RNAs were closely correlated ($r = 0.801$, $P < 0.001$), whereas there were significant but weak correlations between serum HCV RNA and liver positive- and negative-strand HCV RNAs ($r = 0.474$, $P = 0.001$ and $r = 0.476$, $P = 0.001$, resp.).

The relationship between hepatic gene expression and HCV loads was further investigated with regard to treatment responsiveness at later time points. Like liver tissues showing cEVR, none of the mRNA expression levels showed a relationship with hepatic HCV loads when liver tissues showing VR24 and SVR were analyzed. On the other hand, the expression of a certain set of the PRR signaling genes, albeit not all, showed significant correlations with hepatic HCV loads in nonresponders. Positive- and/or negative-strand HCV

RNA(s) were positively correlated with mRNA expression of RIG-I ($r = 0.797$, $P < 0.001$ and $r = 0.744$, $P = 0.002$), TRIF ($r = 0.659$, $P = 0.010$ and $r = 0.620$, $P = 0.018$), IPS-1 ($r = 0.563$, $P = 0.036$ and $r = 0.538$, $P = 0.047$), and IRF3 ($r = 0.647$, $P = 0.012$ and $r = 0.521$, $P = 0.056$, resp.) in liver tissues nonresponsive at week 24 (Table 2). When liver tissues not attaining SVR were analyzed, positive- and/or negative-strand HCV RNA(s) were positively correlated with mRNA expression of TLR3 ($r = 0.632$, $P = 0.009$ and $r = 0.632$, $P = 0.009$), RIG-I ($r = 0.760$, $P < 0.001$ and $r = 0.693$, $P = 0.003$), and IRF3 ($r = 0.545$, $P = 0.029$ and $r = 0.426$, $P = 0.099$, resp.) (Table 3). Again, the relationship of circulating HCV RNA with hepatic mRNA expression was not evident, regardless of treatment responsiveness. A significant relationship was seen only between serum HCV RNA and RIG-I mRNA expression in liver tissues without SVR ($r = 0.511$, $P = 0.043$).

4. Discussion

Previous studies showed that HCV proteins produced in infected cells impair the PRR signaling involved in IFN- β production via cleavage of TRIF and IPS-1 [3–5] and further impair downstream IFN action in various ways [6]. It has also been demonstrated that impairment of the host antiviral response by HCV depends on HCV propagation. The cleavage of IPS-1 by HCV NS3/4A serine protease is more extensive in the liver with high levels of HCV propagation [7, 8]. Hepatic mRNA expression of downstream IFN-stimulated genes (ISGs) is negatively correlated with hepatic HCV loads, indicating HCV replication-related impairment of antiviral signaling involved in ISG expression [8]. How hepatic HCV propagation is related to the expression of various PRR signaling genes involved in IFN- β production has not been fully clarified.

Of the PRR signaling genes, some are known ISGs (TLR3, and RIG-I), while others (TRIF, IPS-1 and IRF3) are not. We

(a)

FIGURE 1: Continued.

FIGURE 1: Relationship between HCV replication and hepatic PRR signaling gene expression in 31 patients nonresponsive at week 12. HCV replication was assessed by liver positive- and negative-strand HCV RNAs and circulating HCV RNA.

TABLE 3: Correlations between HCV replication (liver positive- and negative-strand HCV RNAs and circulating HCV RNA) and hepatic PRR signaling gene expression regarding posttreatment virologic response.

Hepatic gene expression		Patients with SVR (<i>n</i> = 22)			Patients without SVR (<i>n</i> = 16)		
		Liver HCV RNA		Serum HCV RNA	Liver HCV RNA		Serum HCV RNA
		+Strand	–Strand		+Strand	–Strand	
TLR3 mRNA	<i>r</i>	0.021	0.132	0.068	0.632	0.632	0.214
	<i>P</i>	0.925	0.557	0.763	0.009	0.009	0.427
RIG-I mRNA	<i>r</i>	0.192	0.243	–0.176	0.760	0.693	0.511
	<i>P</i>	0.392	0.277	0.432	<0.001	0.003	0.043
TRIF mRNA	<i>r</i>	0.109	0.200	–0.214	0.465	0.485	–0.029
	<i>P</i>	0.631	0.373	0.339	0.069	0.057	0.914
IPS-1 mRNA	<i>r</i>	0.072	0.131	–0.260	0.389	0.365	0.159
	<i>P</i>	0.750	0.562	0.243	0.137	0.165	0.556
IRF3 mRNA	<i>r</i>	0.056	0.023	–0.380	0.545	0.426	0.175
	<i>P</i>	0.803	0.918	0.081	0.029	0.099	0.516
IFN-β mRNA	<i>r</i>	0.034	–0.078	–0.107	0.158	0.112	–0.267
	<i>P</i>	0.882	0.730	0.634	0.560	0.680	0.318

found that pretreatment hepatic mRNA expression of these genes uniformly increased in parallel with hepatic HCV loads in patients not attaining early antiviral response to PEG-IFN and ribavirin. In striking contrast, these increases were absent in responders. In IFN nonresponders, HCV replication-related increase in the mRNA expression of the PRR signaling genes was not accompanied with that in IFN-β mRNA expression. The mechanism underlying these findings remains unclear. Thus far, impairment of IFN production and its action has not been well studied regarding responsiveness to exogenous IFN. Our results may imply differential impairment of the host antiviral response by HCV propagation in liver tissues responsive and nonresponsive to exogenous IFN. HCV propagation may cause more severe impairment in IFN nonresponders compared with responders and, in turn, work host feedback systems to upregulate the PRR signaling gene expression involved in IFN production at the mRNA level. Further studies are needed to address these unresolved issues.

Unlike hepatic HCV loads, circulating HCV loads showed much less evident correlations with the PRR signaling gene expression in IFN nonresponders. This discrepancy may imply that circulating HCV loads do not correctly reflect

HCV loads in liver tissues, which are the key compartments in which viral propagation occurs, and the HCV proteins produced interfere with IFN production and its action. Circulating HCV loads can be modified by various factors after release of HCV particles from hepatocytes, including the degree of immune clearance. Indeed, liver positive- and negative-strand HCV RNAs were closely correlated in our study cohort, whereas serum HCV RNA was weakly correlated with liver positive- and negative-strand HCV RNAs.

5. Conclusions

Hepatic mRNA expression of the PRR signaling genes involved in IFN production showed differential relationship with hepatic HCV loads in responders and nonresponders to IFN-based treatment. In liver tissues of nonresponders, the expression of various PRR signaling genes was uniformly increased at the mRNA levels in parallel with HCV loads. These figures were absent in liver tissues of responders. Given that interference of HCV proteins with IFN production and its action depends on the levels of HCV replication; the findings in nonresponders may reflect a host feedback response to

severe HCV replication-associated impairment of the IFN system.

Conflict of Interests

The authors declare that they have no conflict of interests.

References

- [1] M. Gale Jr. and E. M. Foy, "Evasion of intracellular host defence by hepatitis C virus," *Nature*, vol. 436, no. 7053, pp. 939–945, 2005.
- [2] E. C. Freundt and M. J. Lenardo, "Interfering with interferons: hepatitis C virus counters innate immunity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 49, pp. 17539–17540, 2005.
- [3] E. Meylan, J. Curran, K. Hofmann et al., "Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus," *Nature*, vol. 437, no. 7062, pp. 1167–1172, 2005.
- [4] K. Li, E. Foy, J. C. Ferreón et al., "Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 8, pp. 2992–2997, 2005.
- [5] X. D. Li, L. Sun, R. B. Seth, G. Pineda, and Z. J. Chen, "Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 49, pp. 17717–17722, 2005.
- [6] M. G. Katze, Y. He, and M. Gale Jr., "Viruses and interferon: a fight for supremacy," *Nature Reviews Immunology*, vol. 2, no. 9, pp. 675–687, 2002.
- [7] P. Bellecave, M. Sarasin-Filipowicz, O. Donzé et al., "Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system," *Hepatology*, vol. 51, no. 4, pp. 1127–1136, 2010.
- [8] L. Jouan, L. Chatel-Chaix, P. Melanon et al., "Targeted impairment of innate antiviral responses in the liver of chronic hepatitis C patients," *Journal of Hepatology*, vol. 56, no. 1, pp. 70–77, 2012.
- [9] N. Yuki, S. Matsumoto, M. Kato, and T. Yamaguchi, "Hepatic Toll-like receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin," *Journal of Viral Hepatitis*, vol. 17, no. 2, pp. 130–138, 2010.
- [10] N. Yuki, S. Matsumoto, K. Tadokoro, K. Mochizuki, M. Kato, and T. Yamaguchi, "Significance of liver negative-strand HCV RNA quantitation in chronic hepatitis C," *Journal of Hepatology*, vol. 44, no. 2, pp. 302–309, 2006.
- [11] R. G. Knodell, K. G. Ishak, W. C. Black et al., "Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis," *Hepatology*, vol. 1, no. 5, pp. 431–435, 1981.